Transo-Pharm continues to closely monitor the widespread impact of the coronavirus disease (COVID-19). The safety and well-being of our employees, customers, partners and suppliers remains our top priority. Additionally, we are committed to supporting our public safety and enterprise customers during this time.
A highly skilled team has been put in place and is closely monitoring the situation around the world. We have taken measures to manage the virus’ impact by following guidance from the German Robert Koch Institute, World Health Organization and local governments. These measures include:
2. Update: Given the current Coronavirus (SARS-CoV-2) development it is reassuring that we can continue to ensure stable supply of both products. We have sufficient inventory in our German warehouse.
1. Update: Please find now coronavirus statement issued by Syn-Tech, Taiwan below attached.
As the coronavirus continues to spread in China, the Chinese Government extended the New Year holiday one additional week to February 9th. Some API factories may not re-open until the 16th to help contain the spread of the virus.
API shortages will be expected due to the extension of Chinese New Year.
Transo-Pharm has a significant stock of Epinephrine Base and Bitartrate manufactured by Syn-Tech (Taiwan) available to our global customers.
Transo-Pharm does not expect any shortages in supply due to the coronavirus.
Coronavirus outbreak in China may disrupt global drug supply chains - but not at Transo-Pharm !
We at Transo-Pharm assure always continuous supply of API Phenylephrine HCL from our CMO, Hisoar, China.
The Coronavirus has no negative impact on our supply chain.
Due to extended stocks Transo-Pharm is able to supply the markets from their warehouse in Germany without any disruption. The next production campaign of the API will start earlier in order to have more time for production, release and the transport out of China. A continuous supply of API for the global customers is guaranteed.
Please find our update here